Using a blood marker to judge heart risks after bypass surgery in heart failure
Follows people with heart failure after bypass surgery, using a GDF-15 blood test.
Plain-language title generated from the registry record
Registry title: Risk Stratification of MACE in Heart Failure Patients Who Undergoing CABG
Key facts
- Where
- Tomsk, RussiaSee the site
Where in Russia
- Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesTomsk, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tomsk National Research Medical Center of the Russian Academy of Sciences
- Trial code
- NCT07480915
- Record updated
- 6 October 2026
- Original description
PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG).Read full original descriptionShow less
Risk Stratification of MACE Based on GDF-15 in Heart Failure Patients Who Undergoing Coronary Artery Bypass Grafting: an Observational Multicenter Prospective Study
PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG).
The objective of the study is to develop a method for assessing the risk of adverse cardiovascular events in patients with CAD and HF who have undergone CABG, based on preoperative GDF-15 concentrations.
The study will have a 12-month follow-up period; one in-person visit is planned at the end of the follow-up period. If it is not possible to visit a doctor in person, information will be collected through telephone contact with the patient or his relative or person caring for the patient.
Inclusion: Heart Failure; Planned coronary artery bypass grafting.
Exclusion: Myocardial infarction; Stroke; Need for additional cardiac surgery other than coronary artery bypass grafting (valve repair, aneurysm); Severe comorbidities: active cancer; infiltrative cardiac diseases (sarcoidosis, amyloidosis, storage diseases); autoimmune diseases; acute infectious diseases and exacerbations of chronic somatic diseases; Severe renal dysfunction (GFR <30 ml/min/1.73 m2); Presence of implanted devices.